Mylan N.V. (MYL) : 7 Wall Street analysts covering Mylan N.V. (MYL) believe that the average level the stock could reach for the short term is $59.14. The maximum price target given is $71 and the minimum target for short term is around $51, hence the standard deviation is calculated at $7.47.
Mylan N.V. (MYL) has seen a rise of 1,128,271 shares or 4.4% in the short interest. The remaining shorts are 6.5% of the total floated shares. The net short interest, as on June 30,2016, stood at 26,993,595 shares and the stocks days to cover will be 5 by factoring in the average per day volume of 5,281,945 shares. On June 15,2016, 25,865,324 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Leerink Swann maintains its rating on Mylan N.V. (NASDAQ:MYL). The global brokerage major lowers the current price target from $53 per share to $51 per share. Analysts at the Leerink Swann have a current rating of Outperform on the shares. The rating by the firm was issued on May 4, 2016.
Mylan N.V. (NASDAQ:MYL): stock turned positive on Thursday. Though the stock opened at $45.85, the bulls momentum made the stock top out at $45.97 level for the day. The stock recorded a low of $45.28 and closed the trading day at $45.38, in the green by 0.18%. The total traded volume for the day was 2,502,777. The stock had closed at $45.3 in the previous days trading.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.